Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Quillichew ER is a cherry-flavored, extended-release chewable tablet containing methylphenidate hydrochloride. It is FDA-approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. Quillichew ER is designed with approximately 30% immediate-release and 70% extended-release methylphenidate, providing both rapid onset and sustained symptom control throughout the day. It is manufactured by Tris Pharma and marketed by Pfizer. Because it is a chewable tablet, Quillichew ER is particularly useful for patients who have difficulty swallowing pills.
Quillichew ER works by blocking the reuptake of norepinephrine and dopamine into presynaptic neurons in the brain. This increases the concentration of these neurotransmitters in the synaptic cleft, which helps improve attention, focus, and impulse control in patients with ADHD. The extended-release chewable formulation is taken once daily in the morning and provides symptom relief that lasts throughout the day.
Quillichew ER has a findability score of 45 out of 100, meaning it can be moderately difficult to locate in stock. As a Schedule II stimulant, Quillichew ER has been affected by the ongoing ADHD medication shortage driven by increased demand, DEA production quotas, and supply chain constraints. While the manufacturer Tris Pharma reports general availability, individual pharmacies may be out of stock at any given time. Using Medfinder can help you quickly identify pharmacies near you that currently have Quillichew ER in stock.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Quillichew ER can be prescribed by a variety of healthcare providers, including pediatricians, child and adolescent psychiatrists, general psychiatrists, family medicine physicians, primary care doctors, internists, and neurologists. Because it is a Schedule II controlled substance, it requires a written prescription and cannot be called in or refilled without a new prescription in most states. Telehealth providers may also prescribe Quillichew ER where permitted by state law.
Yes, Quillichew ER is classified as a Schedule II (CII) controlled substance by the DEA. This means it has a high potential for abuse and dependence. Prescriptions cannot be refilled and typically require a new written prescription each month. The FDA boxed warning states that CNS stimulants, including Quillichew ER, should be assessed for abuse risk prior to prescribing, and patients should be monitored for signs of abuse and dependence during therapy.
Serious side effects may include cardiovascular events, increased blood pressure and heart rate, psychiatric symptoms, peripheral vasculopathy, long-term growth suppression, and seizures. Contact your healthcare provider immediately if you experience any serious side effects.
Note: Quillichew ER contains phenylalanine and should be used with caution in patients with phenylketonuria (PKU).
Quillichew ER is a valuable ADHD treatment option, especially for patients who have difficulty swallowing traditional pills. Its cherry-flavored chewable format and once-daily dosing make it convenient for children and adults alike. However, as a Schedule II controlled substance affected by the ongoing stimulant shortage, finding Quillichew ER in stock can be challenging. No generic version is currently available, which contributes to its higher cost. If you have commercial insurance, the Tris Pharma Co-pay Savings Program may reduce your out-of-pocket cost to as little as $25 per fill. Uninsured or underinsured patients may qualify for assistance through Pfizer RxPathways. Use Medfinder to locate pharmacies with Quillichew ER in stock near you.
%2C%20Color%3DOriginal.png)
